Evaluation of drug-drug interactions of a novel potent FLT3 inhibitor SKLB1028 in healthy subjects

• Egile Nagusiak: Jingcheng Chen (Egilea), Jingxuan Wu (Egilea), Nini Guo (Egilea), Yuqin Song (Egilea), Lijun Li (Egilea), Bingyan Wang (Egilea), Jiangshuo Li (Egilea), Mengyu Hou (Egilea), Hang Yin (Egilea), Meijuan Zhang (Egilea), Yanhong Kong (Egilea), Xiaofang Wu (Egilea), Ran Li (Egilea), Le Wu (Egilea), Qiannan Gao (Egilea), Ruihua Dong (Egilea)
• Formatua: Liburua
• Argitaratua: Wiley, 2024-11-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Abstract SKLB1028 is a novel multi‐target protein kinase inhibitor under investigation for the treatment of FLT3‐ITD mutated acute myeloid leukemia. Based on the preclinical characterization of SKLB1028 metabolism, three drug-drug interaction clinical studies were performed to investigate the effect...